Finally a Drug For Binge Eating Disorder!
The U.S. Food and Drug Administration (FDA) has finally approved the first medication to treat Binge Eating Disorder (BED). Vyvanse®(lisdexamfetaminedimesylate) brings hope to those struggling to keep up with their unexplained need to eat large amounts of food. Vyvanse® was reviewed under the FDA’s priority review program, which provides for an expedited review of drugs that are intended to treat a serious disease or condition and may provide a significant improvement over available therapies.
BED is a type of feeding and eating disorder in which people lose control over eating and feel deeply embarrassed about their eating habits.In addition to making a person feel guilty after grabbing large amounts of food, it also causes several detrimental physical consequences.
Existing Management Approaches
Although psychotherapies are effective in treatment of BED, not all patients respond to these therapies. Additionally, psychotherapy has not been found to be effective in the treatment of BED associated co-morbid conditions, such as obesity, diabetes, hypertension, bipolar disorder, or depression. Bariatric surgery may reduce binge eating; however there is no confirmed evidence of its efficacy. So far there were no medications specifically prescribed for the treatment of BED. Medications that show effects on moods, appetite, and weight were therefore considered of therapeutic benefits in BED.
Finally, the FDA has expanded the approved uses of Vyvanse® to treat BED in adults. The drug has shown its efficacy in two clinical studies that included 724 adults with moderate-to-severe BED. The studies reported that people taking Vyvanse®showed reduced number of binge eating days per week and had fewer obsessive-compulsive binge eating behaviors compared to those who received placebo. Most common side effects associated with this drug include dry mouth, sleeplessness (insomnia), increased heart rate, constipation, and anxiety.
It is important to note that although the drug can reduce the frequency of binge eating episodes, its efficacy for weight loss has not been studied.
Vyvanse® is marketed by Shire U.S., Inc., based in Wayne, Pennsylvania.
For more information on approval of Vyvanse by FDA please visit http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432543.htm